Progression-Free Survival (PFS) and Tumor Growth with Lanreotide Autogel (LAN) in Patients (Pts) with Enteropancreatic NETs: Results from CLARINET, a Randomized, Double-Blind, Placebo (Pbo)-Controlled Study Abstract #970

Introduction: Prospective data on antiproliferative effects of somatostatin analogs are lacking in grade 2 and non-midgut tumors.
Aim(s): CLARINET prospectively evaluated the antiproliferative activity of LAN in both intestinal and pancreatic NET (grade 1/2).
Materials and methods: CLARINET was a randomized, double-blind, Pbo-controlled study. Pts who had well/moderately differentiated, with Ki-67<10%, non-functioning enteropancreatic NETs, and no SSA or other medical therapy within last 6 mo, received LAN 120mg (n=101) or Pbo (n=103) every 4 wks for 96 wks or until PD/ death. Primary endpoint PFS and tumor response were evaluated based on centrally assessed CT scans.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Professor Martyn Caplin
Keywords: tumor response

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1188 Antitumor Treatment with Lanreotide Autogel 120 mg (LAN) for Enteropancreatic (EP-)NET: Update from the CLARINET Open-Label Extension (OLE) Study
Introduction: In CLARINET, LAN had significant antitumour effects vs placebo (PBO) on metastatic G1/G2 EP-NETs, liver burden ≤ and >25%, and 96% SD prior to LAN.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Martyn Caplin
Authors: Caplin M, Pavel M, Cwikla J B, Phan A T, ...
#1475 Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity with Lanreotide Autogel/Depot (LAN) vs Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data
Introduction: TGR is a novel measure of tumor growth activity that may be more precise than RECIST for evaluating response to treatment of NETs.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr Christine Massien
Keywords: TGR, PFS
#1194 Chromogranin A (CgA) and PFS Outcomes in Lanreotide Autogel (LAN) in Patients with Metastatic Enteropancreatic (EP-) NETs: Data from the CLARINET Study
Introduction: The CLARINET study showed LAN 120 mg prolonged PFS vs. placebo (PBO) in patients with metastatic EP-NETs.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Martyn Caplin
Authors: Caplin M, Pavel M, Cwikla J B, Phan A T, ...
Keywords: lanreotide, biomarker
#898 Evaluation of Tumor Response to Targeted Therapies in Precision-Cut Slices of Human Pancreatic Neuroendocrine Tumors
Introduction: Patients with PNET might benefit from new therapeutic approaches acting on the mTOR signaling pathway. Culture of precision-cut slices could allow testing these molecules in human tumors, allowing personalized treatments.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Margot Bucau
#62 Genome-wide DNA methylation profiling of pancreatic neuroendocrine tumors identifies distinct methylation profiles and differentially methylated gene promoter regions associated with low, medium and high grade tumors
Introduction: Integration of genetics and epigenetics has emerged as a powerful approach to studying cellular differentiation (Mikkelsen et al, 2009) and tumorigenesis (Shen et al, 2007). The study of DNA methylation is of particular importance in cancer, as causal involvement has been demonstrated and it is the most stable of all epigenetic modifications, making it a desirable marker for both early detection and treatment of tumors. Hypermethylation of CpG sites in gene promoter regions leads to decreased gene expression; if such a gene is a tumor suppressor, this leads to carcinogenesis. To date, there have been no studies of genome-wide DNA methylation profiling of NETs. This study sets out to determine the DNA methylation profiles of low, intermediate and high grade pancreatic NET liver metastases with the intention of identifying dysregulated biological pathways in the development of these tumors. A protocol for the analysis formalin-fixed paraffin embedded tissue (FFPE) has also been developed in order to study these tumors in significant numbers following this pilot study.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Christina Thirlwell
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.